NASDAQ:STSA - Satsuma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 250.32 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.14
▼ -0.06 (-1.88%)

This chart shows the closing price for STSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Satsuma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STSA

Analyst Price Target is $11.00
▲ +250.32% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Satsuma Pharmaceuticals in the last 3 months. The average price target is $11.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 250.32% upside from the last price of $3.14.

This chart shows the closing price for STSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Satsuma Pharmaceuticals. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022MizuhoLower Price Target$15.00 ➝ $13.00Low
3/22/2022HC WainwrightReiterated RatingBuy$15.00High
11/14/2021SVB LeerinkReiterated RatingHold$5.00High
11/10/2021MizuhoReiterated RatingBuy$15.00High
6/22/2021MizuhoUpgradeNeutral ➝ Buy$7.00 ➝ $15.00High
6/20/2021SVB LeerinkReiterated RatingHoldLow
6/17/2021HC WainwrightReiterated RatingBuy$15.00High
5/12/2021SVB LeerinkBoost Price TargetMarket Perform$4.00 ➝ $5.00High
4/5/2021MizuhoBoost Price TargetPositive ➝ Neutral$3.50 ➝ $7.00Low
3/2/2021MizuhoReiterated RatingHold$3.50High
3/2/2021Credit Suisse GroupUpgradeUnderperform ➝ Neutral$6.50Medium
11/11/2020MizuhoLower Price TargetNeutral$4.00 ➝ $3.50Medium
9/21/2020HC WainwrightLower Price TargetBuy$35.00 ➝ $7.00Low
9/11/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$35.00 ➝ $4.00Medium
9/11/2020MizuhoDowngradeBuy ➝ Neutral$32.00 ➝ $4.00Low
9/11/2020Credit Suisse GroupDowngradeOutperform ➝ Underperform$33.00 ➝ $4.00Low
8/14/2020Credit Suisse GroupBoost Price TargetOutperform$32.00 ➝ $33.00High
7/27/2020HC WainwrightInitiated CoverageBuy$35.00Low
6/1/2020MizuhoReiterated RatingBuy$32.00Low
5/12/2020MizuhoReiterated RatingBuy$32.00High
5/6/2020MizuhoReiterated RatingBuy$32.00Medium
5/6/2020Credit Suisse GroupReiterated RatingBuy$32.00Medium
4/12/2020MizuhoReiterated RatingBuy$32.00High
3/11/2020SVB LeerinkBoost Price TargetOutperform$20.00 ➝ $35.00High
3/2/2020Credit Suisse GroupBoost Price Target$20.00 ➝ $32.00High
2/5/2020MizuhoInitiated CoverageBuyHigh
10/8/2019SVB LeerinkInitiated CoverageOutperform$20.00Low
10/8/2019Credit Suisse GroupInitiated CoverageOutperform$16.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Satsuma Pharmaceuticals logo
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.14
Low: $3.14
High: $3.45

50 Day Range

MA: $3.67
Low: $2.59
High: $4.24

52 Week Range

Now: $3.14
Low: $2.51
High: $7.48

Volume

8,878 shs

Average Volume

62,743 shs

Market Capitalization

$99.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Satsuma Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Satsuma Pharmaceuticals in the last twelve months: HC Wainwright, Mizuho, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for STSA.

What is the current price target for Satsuma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Satsuma Pharmaceuticals in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 227.4%.
View the latest price targets for STSA.

What is the current consensus analyst rating for Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe STSA will outperform the market and that investors should add to their positions of Satsuma Pharmaceuticals.
View the latest ratings for STSA.

How do I contact Satsuma Pharmaceuticals' investor relations team?

Satsuma Pharmaceuticals' physical mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider's listed phone number is 650-410-3200. The official website for Satsuma Pharmaceuticals is www.satsumarx.com. Learn More about contacing Satsuma Pharmaceuticals investor relations.